Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Kustermann

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Resuscitation|March 20, 2019
Electromyographic reactivity measured with scalp-EEG contributes to prognostication after cardiac arrestMatteo Caporro, Andrea O Rossetti, Andrea Seiler, et al.
Journal of Parkinson'S Disease|February 26, 2026
Quantitative measures of total and phosphorylated alpha-synuclein in skin tissue as potential biomarkers for synucleinopathiesBram L van der Gaag, Janna van Wetering, Martino L Morella, et al.
Nature Medicine|October 8, 2024
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trialGennaro Pagano, Annabelle Monnet, Adriana Reyes, et al.
Parkinsonism & Related Disorders|January 11, 2025
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline dataTania Nikolcheva, Gennaro Pagano, Nathalie Pross, et al.
Molecular Pharmaceutics|November 6, 2025
Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood-Brain BarrierTobias Gustavsson, Thomas Kustermann, Lars Hvass, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled studyTania Nikolcheva, Gennaro Pagano, Judith Anzures-Cabrera, et al.
NPJ Digital Medicine|June 16, 2025
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumabKirsten I Taylor, Florian Lipsmeier, Marzia A Scelsi, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Prasinezumab in Early-Stage Parkinson's DiseaseGennaro Pagano, Kirsten I Taylor, Judith Anzures-Cabrera, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Resuscitation|March 20, 2019
Electromyographic reactivity measured with scalp-EEG contributes to prognostication after cardiac arrestMatteo Caporro, Andrea O Rossetti, Andrea Seiler, et al.
Journal of Parkinson'S Disease|February 26, 2026
Quantitative measures of total and phosphorylated alpha-synuclein in skin tissue as potential biomarkers for synucleinopathiesBram L van der Gaag, Janna van Wetering, Martino L Morella, et al.
Nature Medicine|October 8, 2024
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trialGennaro Pagano, Annabelle Monnet, Adriana Reyes, et al.
Parkinsonism & Related Disorders|January 11, 2025
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline dataTania Nikolcheva, Gennaro Pagano, Nathalie Pross, et al.
Molecular Pharmaceutics|November 6, 2025
Pretargeted Immuno-PET Enables Monoclonal Antibody Imaging Beyond the Blood-Brain BarrierTobias Gustavsson, Thomas Kustermann, Lars Hvass, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled studyTania Nikolcheva, Gennaro Pagano, Judith Anzures-Cabrera, et al.
NPJ Digital Medicine|June 16, 2025
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumabKirsten I Taylor, Florian Lipsmeier, Marzia A Scelsi, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Prasinezumab in Early-Stage Parkinson's DiseaseGennaro Pagano, Kirsten I Taylor, Judith Anzures-Cabrera, et al.
Pageof 2